Myungin Pharm명인제약
317450 · KOSPI · ₩317450 · 명인제약
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩114,072
vs the current price (₩40,200)
- Enterprise value
- ₩1.2T
- Equity value
- ₩1.7T
- WACC
- 7.3%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model is 184% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:
- To match today's price of ₩40,200, the model needs an operating margin of 6.3% every year (it uses 32.2%).
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- ₩88,607
- +120.4%
- Base
- ₩114,072
- +183.8%
- Bull
- ₩155,504
- +286.8%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (32.2%).
Revenue growth
- 3%
How much sales grow that year, compared with the year before.
Default: not enough revenue history, so 3%.
- 3%
How much sales grow that year, compared with the year before.
Default: not enough revenue history, so 3%.
- 3%
How much sales grow that year, compared with the year before.
Default: not enough revenue history, so 3%.
- 3%
How much sales grow that year, compared with the year before.
Default: not enough revenue history, so 3%.
- 3%
How much sales grow that year, compared with the year before.
Default: not enough revenue history, so 3%.
Business
- 32.2%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 1 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 9.7%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 12.1%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 1 annual reports (cash flow statements; equipment and intangibles).
- 38.1%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 1 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.03%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-27.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 56 weeks of weekly returns against KOSPI (official index); raw beta 0.13, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.53%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩287B
- Net debt (borrowings and leases − cash and deposits)
- −₩447B
- + Stakes and investments
- ₩5M
- Associates, long-term financial assets and deposits (book value)
- Shares
- 14,600,000
- Share price
- ₩40,200
- Market cap
- ₩587B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|
| Revenue | ₩287B | ₩296B | ₩305B | ₩314B | ₩323B | ₩333B |
| Growth | — | 3.0% | 3.0% | 3.0% | 3.0% | 3.0% |
| EBIT | ₩92B | ₩95B | ₩98B | ₩101B | ₩104B | ₩107B |
| EBIT margin | 32.2% | 32.2% | 32.2% | 32.2% | 32.2% | 32.2% |
| After-tax EBIT | ₩67B | ₩69B | ₩71B | ₩73B | ₩75B | ₩78B |
| + Depreciation | — | ₩29B | ₩30B | ₩30B | ₩31B | ₩32B |
| − Capital spending | ₩35B | ₩36B | ₩37B | ₩38B | ₩39B | ₩40B |
| − Working capital | — | ₩3.3B | ₩3.4B | ₩3.5B | ₩3.6B | ₩3.7B |
| Free cash flow | — | ₩59B | ₩60B | ₩62B | ₩64B | ₩66B |
| Discount factor | — | 0.932 | 0.868 | 0.809 | 0.753 | 0.702 |
| Present value | — | ₩55B | ₩52B | ₩50B | ₩48B | ₩46B |
Terminal value ₩1.4T, worth ₩967B today: 79% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.3% | ₩118,255 | ₩125,199 | ₩133,739 | ₩144,499 | ₩158,478 |
| 6.8% | ₩110,538 | ₩116,136 | ₩122,886 | ₩131,187 | ₩141,646 |
| 7.3% | ₩104,044 | ₩108,631 | ₩114,072 | ₩120,634 | ₩128,703 |
| 7.8% | ₩98,504 | ₩102,315 | ₩106,774 | ₩112,063 | ₩118,442 |
| 8.3% | ₩93,724 | ₩96,927 | ₩100,631 | ₩104,966 | ₩110,108 |
Now (TTM)
- Market cap
- ₩587B
- Enterprise value
- ₩139B
- P/E
- 7.2×
- P/B
- 0.7×
- P/S
- 2.0×
- EV/EBITDA
- —
- Dividend yield
- 3.7%
Over time (at each year end)
| 2025 | |
|---|---|
| Price | ₩68,900 |
| Market cap | ₩1T |
| P/E | 12.4× |
| P/B | 1.3× |
| P/S | 3.5× |
| EV/EBITDA | — |
| Dividend yield | 2.2% |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Myungin Pharm | 7.2× | 0.7× | 2.0× | — | 3.7% |
| Samsung Biologics | 32.1× | 7.6× | 14.0× | — | 0.0% |
| Celltrion | 27.8× | 2.4× | 8.9× | — | 0.0% |
| Alteogen | 78.8× | 28.4× | 59.9× | — | 0.1% |
| Yuhan | 24.8× | 2.5× | 2.6× | 32.5× | 0.8% |
| SK biopharmaceuticals | 14.6× | 5.7× | 6.8× | — | 0.0% |
| HLB | — | 15.4× | 54.6× | — | 0.0% |
| Similar companies (median) | 27.8× | 6.7× | 11.5× | 32.5× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Myungin Pharm / 명인제약 / 317450 / KRX:317450
Source: KRX statistical information